Price$1.57-0.03 (-1.88%)
01:30 PM07:45 PM
News · 26 weeks70-19%
2026-03-082026-08-30
Mix5190d
- Insider33(65%)
- Other9(18%)
- SEC Filings7(14%)
- Earnings2(4%)
Latest news
25 items- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 7,371 shares, increasing direct ownership by 9% to 89,875 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 6,822 shares, increasing direct ownership by 7% to 100,076 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERChief Medical Officer Faller Douglas Vincent was granted 3,626 shares, increasing direct ownership by 11% to 37,077 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERGeneral Counsel and Corp Sec Eylward Susan was granted 2,525 shares and sold $3,950 worth of shares (2,525 units at $1.56) (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- PRIMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones A patient treated with IMNN-001 will share firsthand perspective on her treatment journey and life following participation in the clinical trial The event will be held on September 23 in New York City and will be webcast live LAWRENCEVILLE, N.J., Aug. 26, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company developing IMNN-001 DNA-mediated IL-12 immunotherapy, today announced that it will host an R&D Day for investors, analysts and media on Wednesday, September 23, 2026, at the Sofitel New
- INSIDERPresident and CEO Lindborg Stacy was granted 6,615 shares, increasing direct ownership by 8% to 93,254 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERChief Medical Officer Faller Douglas Vincent was granted 3,516 shares, increasing direct ownership by 12% to 33,451 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 7,147 shares, increasing direct ownership by 9% to 82,504 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERGeneral Counsel and Corp Sec Eylward Susan was granted 2,449 shares and sold $3,993 worth of shares (2,449 units at $1.63) (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- SECImunon Inc. filed SEC Form 8-K: Leadership Update8-K - Imunon, Inc. (0000749647) (Filer)
- SECSEC Form 10-Q filed by Imunon Inc.10-Q - Imunon, Inc. (0000749647) (Filer)
- SECImunon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Imunon, Inc. (0000749647) (Filer)
- PRIMUNON Reports Second Quarter 2026 Financial Results and Provides Business UpdateIMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by the first half of 2029, supported by strong Phase 2 clinical data showing significant overall survival benefit Company to hold conference call today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the three months and six months ended June 30, 2026, an
- INSIDERDirector Pellizzari Christine A was granted 6,934 shares, increasing direct ownership by 85% to 15,076 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Dentzer James E was granted 6,934 shares, increasing direct ownership by 46% to 21,897 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Fritz Frederick J. was granted 6,934 shares, increasing direct ownership by 49% to 21,031 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERDirector Braun Donald P was granted 6,180 shares, increasing direct ownership by 66% to 15,499 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERGeneral Counsel and Corp Sec Eylward Susan was granted 2,541 shares and sold $3,977 worth of shares (2,541 units at $1.57) (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 6,358 shares, increasing direct ownership by 9% to 75,357 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERChief Medical Officer Faller Douglas Vincent was granted 3,649 shares, increasing direct ownership by 14% to 29,935 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- INSIDERPresident and CEO Lindborg Stacy was granted 5,010 shares, increasing direct ownership by 6% to 86,639 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
- PRIMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026LAWRENCEVILLE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, August 11, 2026 to discuss financial results for the second quarter ended June 30, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer. To participate in the call, please dial (800) 715-9871 (U.S. and Canada/Toll Free) or (646) 307-
- PRIMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian CancerEnrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company’s large, randomized Phase II study, OVATION 2Strong enrollment demonstrates the confidence of principal investigators from prestigious cancer institutions in the trial design and its potential for a successful outcomeEnrollment ahead of plan across all study sites. Additional sites opening on pace with projections LAWRENCEVILLE, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN) ("IMUNON" or "the Company"), a clinical-stage biotechnology company developing its novel DNA-mediated immunotherapies, today is providing a progre
- PRIMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and DevelopmentTranslational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism First-of-its-kind meeting spotlights IMNN-001 as one of the novel technologies shaping the future of cancer drug discovery and development LAWRENCEVILLE, N.J., July 23, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that new data on IMNN-001, the Company's DNA-based interleukin-12 (IL-12) immunotherapy for advanced ovarian cancer, will be featured in a poster presentation at the inaugural AACR Conference on Drug Discovery and Deve
- INSIDERExecutive Chairman of Board Tardugno Michael H was granted 4,603 shares, increasing direct ownership by 7% to 68,999 units (SEC Form 4)4 - Imunon, Inc. (0000749647) (Issuer)
IMNN FAQ
4 questionsWhere does IMNN stock trade?
Imunon Inc. (IMNN) is listed on NASDAQ.What sector and industry is IMNN in?
Imunon Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to IMNN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IMNN side-by-side with any of them on Quantisnow.How can I track IMNN on Quantisnow?
Quantisnow aggregates Imunon Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMNN to receive live email and push alerts on every new disclosure.